Exclusive: Immunotherapy developer Dynavax explores options for Hepatitis B drug-sources

(Reuters) – Dynavax Technologies Corporation, a biotechnology company focused on drugs that harness the immune system to combat disease, is reviewing strategic options for its hepatitis B vaccine, which could include a potential sale or licensing deal, people familiar with the matter said.

Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *